Increased nuclear factor-κB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Medical Hypotheses

Volumn 79, Issue 5, 2012, Pages 607-613

  Morris, Gerwyn ^a   Maes, Michael ^b  

^a Tir Na Nog   (United Kingdom)

^b Maes Clinics at Tria   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FATTY ACID SYNTHASE; GLUCOSE TRANSPORTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTIC ACID; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN;

ANAEROBIC GLYCOLYSIS; APOPTOSIS; ARTICLE; CELL DENSITY; CHRONIC FATIGUE SYNDROME; CHRONIC INFLAMMATION; COGNITIVE DEFECT; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXERCISE; EXHAUSTION; FATIGUE; GLIA CELL; GLYCOLYSIS; HUMAN; LACTATE BLOOD LEVEL; MALAISE; MITOCHONDRION; NERVE CELL DEGENERATION; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PROTEIN DEPLETION; PROTEIN EXPRESSION; SKELETAL MUSCLE; SURVIVAL;

EID: 84867334006     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.07.034     Document Type: Article

References (139)

1. Fukuda K., Straus S., Hickie I., Sharpe M., Dobbins J., Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994, 121:953-959.
2. Reeves W., Wagner D., Nisenbaum R., et al. Chronic fatigue syndrome - a clinically empirical approach to its definition and study. BMC Med 2005, 3:19.
3. Sharpe M.C., Archard L.C., Banatvala J.E., et al. A report-chronic fatigue syndrome: guidelines for research. J R Soc Med 1991, 84:118-121.
4. Maes M, Twisk FNM, Johnson C (2012) Myalgic Encephalomyelitis (ME), Chronic Fatigue Syndrome (CFS), and Chronic Fatigue (CF) are distinguished accurately: results of supervised learning techniques applied on clinical and inflammatory data. Psychiatr Res, in press.
5. Twisk F.N., Maes M. A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinol Lett 2009, 30(3):284-299.
6. White P.D., Goldsmith K.A., Johnson A.L., et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011, 377:823-836.
7. Jason L.A., Choi M. Dimensions and assessment of fatigue. Fatigue science human health 2008, 1-16. Springer, Tokyo. Y. Watanabe, B. Evengard, B.H. Natelson, L.A. Jason, H. Kuratsune (Eds.).
8. Maes M., Twisk F.N. Chronic fatigue syndrome: harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med 2010, 8:35.
9. Carruthers B.M., van de Sande M.I., De Meirleir K.L., et al. Myalgic Encephalomyelitis: International Consensus Criteria. J Intern Med 2011, 270(4):327-338.
10. Tirelli U., Chierichetti F., Tavio M., et al. Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med 1998, 105:54S-58S.
11. Cook D.B., Lange G., DeLuca J., Natelson B.H. Relationship of brain MRI abnormalities and physical functional status in chronic fatigue syndrome. Int J Neurosci 2001, 107:1-6.
12. Chen R., Liang F.X., Moriya J., et al. Chronic fatigue syndrome and the central nervous system. J Int Med Res 2008, 36:867-874.
13. Broderick G., Fuite J., Kreitz A., Vernon S.D., Klimas N., Fletcher M.A. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 2010, 24:1209-1217.
14. Lorusso L., Mikhaylova S.W., Capelli E., Ferrari D., Ngonga G.K., Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8:287-291.
15. Fletcher M.A., Zeng X.R., Maher K., et al. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV. PLoS One 2010, 5:e10817.
16. Mihaylova I., DeRuyter M., Rummens J.L., Basmans E., Maes M. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: 35 evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett 2007, 28:477-483.
17. Myhill S., Booth N.E., McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009, 2:1-16.
18. Pieczenik S.R., Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007, 83:84-92.
19. Behan W.M., More I.A., Behan P.O. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991, 83:61-65.
20. Streeten D.H., Thomas D., Bell D.S. The roles of orthostatic hypotension, orthostatic tachycardia and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. Am J Med 2000, 320:1-8.
21. Peckerman A., LaManca J.J., Dahl K.A., Chemitiganti R., Qureishi B., Natelson B.H. Abnormal impedance cardiography predicts symptom severity in Chronic Fatigue Syndrome. Am J Med Sci 2003, 326:55-60.
22. Hollingsworth K.G., Jones D.E., Taylor R., Blamire A.M., Newton J.L. Impaired cardiovascular response to standing in chronic fatigue syndrome. Eur J Clin Invest 2010, 40:608-615.
23. Maes M. Inflammatory cascades in chronic fatigue syndrome. In: Pharmacopsychiatry. Leonard B, Halaris A, Karger; 2012.
24. Maes M., Twisk F.N. Why Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS. Neuro Endocrinol Lett 2009, 30:677-693.
25. Maes M., Mihaylova I., Bosmans E. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett 2007, 28(4):456-462.
26. Maes M., Mihaylova I., Kubera M., Bosmans E. Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett 2007, 28(4):463-469.
27. Maes M., Mihaylova I., De Ruyter M. Lower serum zinc in Chronic Fatigue Syndrome (CFS): relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. J Affect Disord 2006, 90(2-3):141-147.
28. Maes M., Mihaylova I., Leunis J.C. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett 2006, 27(5):615-621.
29. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Coenzyme Q10 deficiency in Myalgic ncephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett 2009, 30(4):470-476.
30. Meeus M., Mistiaen W., Lambrecht L., Nijs J. Immunological similarities between cancer and chronic fatigue syndrome: the common link to fatigue?. Anticancer Res 2009, 29:4717-4726.
31. Vermeulen R.C.W., Kurk R.M., Visser F.C., Sluiter W., Scholte H.R. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J Transl Med 2010, 8:93.
32. Duley J.A., Garrick D.P., Pratt D.A. Raised plasma adenosine associated with chronic fatigue syndrome: a preliminary study. J Chr Fatig Syndr 2000, 7:77-85.
33. Gong G., Waris G., Tanveer R., Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB. Proc Natl Acad Sci USA 2001, 98:9599-9604.
34. Martindale J.L., Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002, 192:1-15.
35. Grivennikov S.I., Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010, 21:11-19.
36. Lee H., Herrmann A., Deng J.H., et al. Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 2009, 15:283-293.
37. O'Malley JT (2009) STAT protein regulation of FOXP3 expression and inflammatory cytokine production in T helper cell subsets. Ph.D. Doctoral dissertation. Indiana University. Available from IUPUI Scholar Works. http://hdl.handle.net/1805/1872.
38. Huehn J., Polansky J.K., Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?. Nat Rev Immunol 2009, 9:83-89.
39. Ak P., Levine A.J. P53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB J 2010, 24:3643-3652.
40. Niu G., Wright K.L., Ma Y., et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 2005, 25:7432-7440.
41. Lu Y., Zhang K., Li C., et al. Piwil2 suppresses p53 by inducing phosphorylation of signal transducer and activator of transcription 3 in tumor cells. PLoS ONE 2012, 7(1):e30999.
42. Matoba S., Kang J.G., Patino W.D., et al. P53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
43. Assaily W., Benchimol S. Differential utilization of two ATP-generating pathways is regulated by p53. Cancer Cell 2006, 10:4-6.
44. Zhang X.D., Qin Z.H., Wang J. The role of p53 in cell metabolism. Acta Pharmacol Sin 2010, 31:1208-1212.
45. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., Chumakov P.M. The antioxidants function of the p53 tumor suppressor. Nature Med 2005, 11:1306-1313.
46. Ding B., Chi S.G., Kim S.H., et al. Role of p53 in antioxidant defense of HPV-positive cervical carcinoma cells following H2O2 exposure. J Cell Sci 2007, 120:2284-2294.
47. Yoon K.A., Nakamura Y., Arakawa H. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet 2004, 49:134-140.
48. Tan M., Li S., Swaroop M., et al. Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem 1999, 274:12061-12066.
49. Hussain S.P., Amstad P., He P., et al. P53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 2004, 64:2350-2356.
50. O'Connor J.C., Wallace D.M., O'Brien C.J., Cotter T.G. A novel antioxidant function for the tumor-suppressor gene p53 in the retinal ganglion cell. Invest Ophthalmol Vis Sci 2008, 49:4237-4244.
51. Bensaad K., Tsuruta A., Selak M.A., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
52. Velasco-Miguel S., Buckbinder L., Jean P., et al. PA26, a novel target of the p53 tumor suppressor and member of 41 the GADD family of DNA damage and growth arrest inducible genes. Oncogene 1999, 18:127-137.
53. Budanov A.V., Sablina A.A., Feinstein E., Koonin E.V., Chumakov P.M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004, 304:596-600.
54. Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 2010, 107:7455-7460.
55. Cano C.E., Gommeaux J., Pietri S., et al. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res 2009, 69:219.
56. Ibrahim M.M., Razmara M., Nguyen D., Donahue R.J., Wubah J.A., Knudsen T.B. Altered expression of mitochondrial 16S ribosomal RNA in p53-deficient mouse embryos revealed by differential display. Biochim Biophys Acta 1998, 1403:254-264.
57. Kawauchi K., Araki K., Tobiume K., Tanaka N. P53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008, 10:611-618.
58. Johnson RF, Perkins ND (2012) Nuclear factor-κB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends Biochem Sci May 23. [Epub ahead of print].
59. Zhang C., Lin M., Wu R., et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. PNAS 2011, 108:16259-16264.
60. Johnson R.F., Witzel I.I., Perkins N.D. P53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-κB. Cancer Res 2011, 71:5588-5597.
61. Mauro C., Leow S.C., Anso E., et al. NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol 2011, 13:1272-1279.
62. Wisloff U., Najjar S.M., Ellingsen O., et al. Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science 2005, 307:418-420.
63. Saleem A., Adhihetty P.J., Hood D.A. Role of p53 in mitochondrial biogenesis and apoptosis in skeletal muscle. Physiol Genomics 2009, 37:58-66.
64. Yoshida Y., Izumi H., Torigoe T., et al. P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res 2003, 63(13):3729-3734.
65. Park J.Y., Wang P.Y., Matsumoto T., et al. P53 improves aerobic exercise capacity and augments skeletal muscle mitochondrial DNA content. Circ Res 2009, 105:705-712.
66. Xiang H., Hochman D.W., Saya H., Fujiwara T., Schwartzkroin P.A., Morrison R.S. Evidence for p53-mediated modulation of neuronal viability. J Neurosci 1996, 16:6753-6765.
67. Luo Y., Shen H., Hoffer B. Abstract 2505: neuronal-specific loss of p53 function in forebrain neurons is protective against ischemic injury. Stroke 2012, 43:A2505.
68. Aloyz R.S., Bamji S.X., Pozniak C.D., et al. P53 Is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors. J Cell Biol 1998, 143:1691-1703.
69. Park S.Y., Jeong M.S., Jang S.B. In vitro binding properties of tumor suppressor p53 with PUMA and NOXA. Biochem Biophys Res Commun 2012, 420(2):350-356.
70. Culmsee C., Mattson M.P. P53 in neuronal apoptosis. Biochem Biophys Res Commun 2005, 331:761-777.
71. Garden G.A., Guo W., Jayadev S., et al. HIV associated neurodegeneration requires p53 in neurons and microglia. FASEB J 2004, 18:1141-1143.
72. O'Neill L.A., Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997, 20:252-258.
73. Mattson M.P., Meffert M.K. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 2006, 13:852-860.
74. Mattson M.P., Goodman Y., Luo H., Fu W., Furukawa K. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res 1997, 49:681-697.
75. Gutierrez H. NF-κB signalling regulates the growth of neural processes in the developing PNS and CNS. Development 2005, 132:1713-1726.
76. O'Sullivan N.C., Croydon L., McGettigan P.A., Pickering M., Murphy K.J. Hippocampal region-specific regulation of NF-κB may contribute to learning-associated synaptic reorganisation. Brain Res Bull 2010, 81:385-390.
77. Boersma M.C., Dresselhaus E.C., De Biase L.M., Mihalas A.B., Bergles D.E., Meffert M.K. A requirement for nuclear factor-{kappa}B in developmental and plasticity-associated synaptogenesis. J Neurosci 2011, 31:5414-5425.
78. Kaltschmidt B., Ndiaye D., Korte M., et al. NF-κB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol Cell Biol 2006, 26:2936-2946.
79. Ahn H.J., Hernandez C.M., Levenson J.M., Lubin F.D., Liou H.C., Sweatt J.D. C-Rel, an NF-kappaB family transcription factor, is required for hippocampal long-term synaptic plasticity and memory formation. Learn Mem 2008, 15:539-549.
80. Albensi B.C., Mattson M.P. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000, 35:151-159.
81. O'Riordan K.J., Huang I.C., Pizzi M., et al. Regulation of nuclear factor kappaB in the hippocampus by group I metabotropic glutamate receptors. J Neurosci 2006, 26:4870-4879.
82. Kassed C.A., Willing A.E., Garbuzova-Davis S., Sanberg P.R., Pennypacker K.R. Lack of NF-κB p50 exacerbates degeneration of hippocampal neurons after chemical exposure and impairs learning. Exp Neurol 2002, 176:277-288.
83. Meffert M.K., Chang J.M., Wiltgen B.J., Fanselow M.S., Baltimore D. NF-κB functions in synaptic signaling and behavior. Nature Neuroscience 2003, 6:1072-1078.
84. O'Mahony A., Raber J., Montano M., et al. NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity. Mol Cell Biol 2006, 26:7283-7298.
85. Mattson M.P., Culmsee C., Yu Z., Camandola S. Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem 2000, 74:443-456.
86. Mattson M.P. NF-kappaB in the survival and plasticity of neurons. Neurochem Res 2005, 30:883-893.
87. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36(2):764-785.
88. Moylan S, Maes M, Wray NR, Berk M (2012) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry Apr 24. doi: 10.1038/mp.2012.33. [Epub ahead of print] PubMed PMID: 22525486.
89. Silver I.A., Erecinska M. Glucose-induced intracellular ion changes in sugar-sensitive hypothalamic neurons. J Neurophysiol 1998, 79:1733-1745.
90. Kann O., Kovacs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 2007, 292:C641-C657.
91. Brunner E.A., Cheng S.C., Berman M.L. Effects of anesthesia on intermediary metabolism. Ann Rev Med 1975, 26:391-401.
92. Kagawa Y. ATP synthase: from single molecule to human bioenergetics. Proc Jpn Acad Ser B Phys Biol Sci 2010, 86:667-693.
93. Yeung S.J., Pan J., Lee M.H. Roles of p53, Myc and HIF-1 in Regulating Glycolysis - the Seventh Hallmark of Cancer. Cell Mol Life Sci 2008, 65:3981-3999.
94. Ma W., Sung H.J., Park J.Y., Matoba S., Hwang P.M. A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr 2007, 39:243-246.
95. Bensaad K., Vousden K.H. P53: new roles in metabolism. Trends Cell Biol 2007, 17:286-291.
96. Olovnikov I.A., Kravchenko J.E., Chumakov P.M. Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin Cancer Biol 2009, 19:32-41.
97. Ramanathan A., Wang C., Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005, 102:5992-5997.
98. Zhou S., Kachhap S., Singh K.K. Mitochondrial impairment in p53-deficient human cancer cells. Mutagenesis 2003, 18:287-292.
99. Seppet E., Gruno M., Peetsalu A., et al. Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci 2009, 10:2252-2303.
100. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120(4):483-495.
101. Petrozzi L., Ricci G., Giglioli N.J., Siciliano G., Mancuso M. Mitochondria and neurodegeneration. Biosci Rep 2007, 27:87-104.
102. Mancuso M., Siciliano G., Filosto M., Murri L. Mitochondrial dysfunction and Alzheimer's disease: new developments. J Alz Dis 2006, 9:111-117.
103. Mancuso C., Scapagini G., Curro D., et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 2007, 12:1107-1123.
104. Murphy M.P. Mitochondria- a neglected drug target. Curr Opin Investig Drugs 2009, 10(10):1022-1024.
105. Gardner A., Boles R.G. Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. Biopsychosoc Med 2008, 2:7.
106. Fadic R., Johns D.R. Clinical spectrum of mitochondrial diseases. Semin Neurol 1996, 16:11-20.
107. Fattal O., Link J., Quinn K., Cohen B.H., Franco K. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr 2007, 12:429-438.
108. Smeitink J.A. Mitochondrial disorders: clinical presentation and diagnostic dilemmas. J Inherit Metab Dis 2003, 26:199-207.
109. Chinnery P.F., Turnbull D.M. Mitochondrial medicine. Quart J Med 1997, 90:657-667.
110. Cohen B.H., Gold D.R. Mitochondrial cytopathies in adults: what we know so far. Cleveland Clin J Med 2001, 68:625-642.
111. Schmiedel J., Jackson S., Schafer J., Reichmann H. Mitochondrial cytopathies. J Neurol 2003, 250:267-277.
112. Deschauer M., Muller T., Wieser T., Schulte-Mattler W., Kornhuber M., Zierz S. Hearing impairment is common in various phenotypes of the mitochondrial DNA A3243G mutation. Arch Neurol 2001, 58:1885-1888.
113. Holmgren D., Whhlander H., Eriksson B.O., Oldfors A., Holme E., Tulinius M. Cardiomyopathy in children with mitochondrial disease. Clinical course and cardiological findings. Eur Heart J 2003, 24:280-288.
114. Nishino I., Spinazzola A., Papadimitriou A., et al. Mitochondrial neurogastrointestinal encephalomyopathy, an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000, 47:792-800.
115. Korres S.G., Manta P.B., Balatsouras D.G., Papageorgiou C.T. Audiological assessment in patients with mitochondrial myopathy. Scand Audiol 1999, 28:231-240.
116. Chinnery P.F., Elliot C., Green G.R., et al. The spectrum of hearing loss due to mitochondrial DNA defects. Brain 2000, 123:82-92.
117. Yen M.Y., Wei Y.H., Liu J.H. Stargardt's type maculopathy in a patient with 11778 Leber's optic neuropathy. J Neuroophthalmol 1996, 16:120-123.
118. Smith P.R., Bain S.C., Good P.A., et al. Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness caused by the mitochondrial DNA 3243 tRNA(Leu) A to G mutation. Ophthalmology 1999, 106:1101-1108.
119. Boonstra F., Claerhout I., Hol F., Smit G., Collenburg V.V., Meire F. Corneal decompensation in a boy with Kearns-Sayre syndrome. Ophthalmic Genet 2002, 23:247-251.
120. Norby S., Lestienne P., Nelson I., et al. Juvenile Kearns-Sayre syndrome initially misdiagnosed as a psychosomatic disorder. J Med Genet 1994, 31:45-50.
121. Mai F.M., Merskey H. Briquet's treatise on hysteria. A synopsis and commentary. Arch Gen Psychiatry 1980, 37:1401-1405.
122. Taivassalo T., Jensen T.D., Kennaway N., DiMauro S., Vissing J., Haller R.G. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain 2003, 126:413-423.
123. Haller R.G., Lewis S.F., Estabrook R.W., et al. Exercise intolerance, lactic acidosis, and abnormal cardiopulmonary regulation in exercise associated with adult skeletal muscle cytochrome c oxidase deficiency. J Clin Invest 1989, 84:155-161.
124. Andreu A.L., Hanna M.G., Reichmann H., et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med 1999, 341:1037-1044.
125. Petty R.K., Harding A.E., Morgan-Hughes J.A. The clinical features of mitochondrial myopathy. Brain 1986, 109:915-938.
126. Kruse J.P., Gu W. P53 aerobics: the major tumor suppressor fuels your workout. Cell Metabol 2006, 4:1-3.
127. Cognato G.P., Vuaden F.C., Savio L.E., et al. Nucleoside triphosphate diphosphohydrolases role in the pathophysiology of cognitive impairment induced by seizure in early age. Neuroscience 2011, 180:191-200.
128. Betourne A., Bertholet A.M., Labroue E., et al. Involvement of hippocampal CA3 K(ATP) channels in contextual memory. Neuropharmacology 2009, 56:615-625.
129. Du F., Zhu X.H., Zhang Y., et al. Tightly coupled brain activity and cerebral ATP metabolic rate. Proc Natl Acad Sci USA 2008, 105:6409-6414.
130. Ikeda S.R., Dunlap K. Calcium channels diversify their signaling portfolio. Nature Neurosci 2007, 10:269-271.
131. Axelrod J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol Rev 1966, 18:95-113.
132. Flynn D.D., Kloog Y., Potter L.T., Axelrod J. Enzymatic methylation of the membrane-bound nicotinic acetylcholine receptor. J Biol Chem 1982, 257:9513-9517.
133. Axelrod J., Hirata F. Phospholipid methylation and membrane function. Ann N Y Acad Sci 1981, 373:51-53.
134. Goodwin J.S., Goodwin J.M., Garry P.J. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983, 249:2917-2921.
135. Bell I.R., Edman J.S., Selhub J., et al. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr Scand 1992, 86:386-390.
136. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995, 274(13):1049-1057.
137. Ramaekers V.T., Husler M., Opladen T., Heimann G., Blau N. Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics 2002, 33:301-308.
138. Wollack J.B., Makori B., Ahlawat S., et al. Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem 2008, 104:1494-1503.
139. Obeid R., Kostopoulos P., Knapp J.P., et al. Biomarkers of folate and vitamin B12 are related in blood and cerebrospinal fluid. Clin Chem 2007, 53:326-333.